Business
Danaher provides life-sciences, biotechnology and diagnostics instruments and consumables.
Danaher: Revenue grew 2.9% to $24.568B from $23.875B. Net income declined 7.3% to $3.614B from $3.899B. Free cash flow declined 0.7% to $5.26B from $5.296B. Operating margin contracted 128 bps to 19.09%. Danaher's annual comparison also shows inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 2.9%OK
- Profitability — Net income declined 7.3% to $3.614B from $3.899BWatch
- Cash flow — Free cash flow declined 0.7% to $5.26B from $5.296BWatch
- Margins — Operating margin contracted 128 bps to 19.09%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 10 salesWatch
Where the revenue comes from
Fiscal 2025, as DANAHER CORP /DE/ reports it. History and quarterly detail are in the app.
- Diagnostics$9.9B
- Life Sciences$7.3B
- Biotechnology$7.3B
Leadership changes
From DANAHER CORP /DE/'s own filings, the day they're filed.
- Matthew E. Gugino · Chief Financial Officer · appointmenteff. 2026-02-28
- Jessica L. Mega · Directors · departureeff. 2026-02-05
- Charles W. Lamanna · director · appointmenteff. 2025-02-20
Latest filings
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-21
- 10-Q · Quarterly report2026-07-21
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about DANAHER CORP /DE/, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.